Principal Financial Group Inc. Sells 1,323 Shares of Guardant Health, Inc. (NASDAQ:GH)

Principal Financial Group Inc. lessened its holdings in shares of Guardant Health, Inc. (NASDAQ:GHFree Report) by 10.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 11,805 shares of the company’s stock after selling 1,323 shares during the quarter. Principal Financial Group Inc.’s holdings in Guardant Health were worth $350,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. CWM LLC grew its holdings in Guardant Health by 137.1% in the 3rd quarter. CWM LLC now owns 984 shares of the company’s stock valued at $29,000 after buying an additional 569 shares in the last quarter. BluePath Capital Management LLC bought a new stake in shares of Guardant Health in the third quarter valued at approximately $35,000. Acadian Asset Management LLC acquired a new stake in Guardant Health during the first quarter worth approximately $37,000. Captrust Financial Advisors grew its position in Guardant Health by 33.2% during the second quarter. Captrust Financial Advisors now owns 1,087 shares of the company’s stock worth $44,000 after buying an additional 271 shares in the last quarter. Finally, Belpointe Asset Management LLC increased its stake in Guardant Health by 33.3% during the 1st quarter. Belpointe Asset Management LLC now owns 3,049 shares of the company’s stock worth $71,000 after acquiring an additional 761 shares during the period. Institutional investors own 92.65% of the company’s stock.

Insider Transactions at Guardant Health

In other Guardant Health news, insider Kumud Kalia sold 5,800 shares of the company’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $26.37, for a total value of $152,946.00. Following the completion of the transaction, the insider now directly owns 5,926 shares in the company, valued at approximately $156,268.62. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 6.20% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have issued reports on GH. Raymond James upgraded shares of Guardant Health from a “market perform” rating to an “outperform” rating and set a $27.00 price objective on the stock in a research note on Monday, November 13th. Morgan Stanley lowered their price objective on shares of Guardant Health from $55.00 to $50.00 and set an “overweight” rating for the company in a research report on Wednesday, November 8th. Guggenheim assumed coverage on Guardant Health in a research note on Thursday, December 14th. They issued a “neutral” rating on the stock. Wolfe Research started coverage on Guardant Health in a research report on Wednesday, December 13th. They set a “peer perform” rating for the company. Finally, The Goldman Sachs Group decreased their target price on Guardant Health from $43.00 to $37.00 and set a “buy” rating on the stock in a research report on Monday, January 29th. Two research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to data from MarketBeat, Guardant Health has an average rating of “Moderate Buy” and a consensus price target of $48.00.

Check Out Our Latest Stock Analysis on GH

Guardant Health Price Performance

GH stock opened at $23.23 on Tuesday. Guardant Health, Inc. has a 12-month low of $20.67 and a 12-month high of $41.06. The stock has a market capitalization of $2.74 billion, a price-to-earnings ratio of -5.72 and a beta of 0.99. The company has a current ratio of 5.94, a quick ratio of 5.60 and a debt-to-equity ratio of 4.99. The firm’s 50-day moving average price is $25.15 and its two-hundred day moving average price is $28.28.

Guardant Health Profile

(Free Report)

Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360; Guardant360 LDT; Guardant360 CDx; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.

Recommended Stories

Institutional Ownership by Quarter for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with's FREE daily email newsletter.